Credit Suisse Group assumed coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report released on Monday, 24/7 WallStreet reports. The brokerage issued a neutral rating and a $70.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the company. Wells Fargo & Co decreased their target price on Gilead Sciences from $95.00 to $89.00 and set an outperform rating on the stock in a research report on Tuesday, February 5th. Citigroup restated a buy rating and issued a $100.00 target price on shares of Gilead Sciences in a research report on Tuesday, February 5th. BidaskClub downgraded Gilead Sciences from a buy rating to a hold rating in a research report on Thursday, February 7th. Zacks Investment Research downgraded Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, January 23rd. Finally, JPMorgan Chase & Co. restated a buy rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Tuesday, May 7th. Nine research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $80.57.

Shares of GILD opened at $67.17 on Monday. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. Gilead Sciences has a 12 month low of $60.32 and a 12 month high of $79.61. The company has a market capitalization of $84.81 billion, a price-to-earnings ratio of 10.92, a price-to-earnings-growth ratio of 0.81 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the company earned $1.48 earnings per share. Gilead Sciences’s quarterly revenue was up 3.8% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences will post 6.6 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a yield of 3.75%. Gilead Sciences’s payout ratio is 40.98%.

In related news, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the transaction, the director now owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total value of $173,178.00. Following the transaction, the director now owns 57,560 shares in the company, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,602 shares of company stock worth $1,863,445. 0.20% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in GILD. Athena Capital Advisors LLC acquired a new stake in Gilead Sciences during the fourth quarter worth $27,000. Capital Financial Planning LLC acquired a new position in Gilead Sciences during the 4th quarter worth $27,000. Creative Financial Designs Inc. ADV grew its stake in Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 165 shares in the last quarter. Claybrook Capital LLC acquired a new position in Gilead Sciences during the 4th quarter worth $32,000. Finally, Trustcore Financial Services LLC acquired a new position in Gilead Sciences during the 1st quarter worth $34,000. Hedge funds and other institutional investors own 78.68% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: Understanding the different types of bonds

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.